The utility of combined mutations and microRNA expression profiling in assessing cancer risk in thyroid nodules

ATA 2017, Victoria, BC, Canada
  • To correlate real-world results of:
    • Bethesda (BDC) classification
    • Mutation panel (ThyGENX®)
    • Two-tiered (positive, negative) miRNA classifier (ThyraMIR®)
  • To examine the projected real-world absolute risk of cancer of BDC III and BDC IV nodules given mutation panel and miRNA classifier results

Scroll to Top